retatrutide nejm 2023 obesity trial ly3437943 Retatrutide: A Triple Agonist Shaping the Future of Metabolic Care Retatrutide — Investigational Triple Agonist

People have coined terms like Ozempic face to describe the hollow or sagging appearance of the face following rapid weight loss, precisely because individuals cannot control where the weight comes off

Your healthcare provider will help you choose the best option based on factors like: Your medical history and current health status Your weight loss goals Your risk of potential side effects Your insurance coverage and ability to access the medication The availability of compounded versions, which may offer cost savings However, its always important to discuss the pros and cons of compounded medications with your healthcare provider

Kleihues P, Burger PC, Scheithauer BW

Who runs clinical trials